CTIS2023-510509-17-00招募中1 期
A Phase 1/2 First in Human Study of the Menin-MLL (KMT2A) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia - KO-MEN-001
Kura Oncology Inc.0 个研究点目标入组 205 人开始时间: 2024年6月6日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 205
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •1. Relapsed/refractory (R/R) acute myeloid leukemia (AML) defined as those who have also failed or are not appropriate for any approved standard-of-care (SOC) therapies or hematopoietic stem cell transplant (HSCT)with reappearance of = 5% blasts in the bone marrow (BM), 2. = 18 years of age, 3. Eastern Cooperative Oncology Group performance status of = 2, and a life expectancy of at least 2 months, 4. Peripheral white blood cell counts = 30,000/µ
排除标准
- •1. Diagnosis of acute promyelocytic leukemia or chronic myelogenous leukemia in blast crisis, 10. Has an active uncontrolled acute or chronic systemic fungal, bacterial, viral, or other infection, 11. Significant cardiovascular disease including unstable angina pectoris, uncontrolled hypertension or arrhythmia, history of cerebrovascular accident including transient ischemic attack within the past 6 months, congestive heart failure (New York Heart Association Class III or IV) related to primary cardiac disease, ischemic or severe valvular heart disease, or a myocardial infarction within 6 months prior to the first dose of study treatment, 12. Mean corrected QT interval by Fredericia's formula > 480 ms on triplicate electrocardiograms, 2. Donor lymphocyte infusion < 30 days prior to study entry, 3. Clinically active central nervous system (CNS) leukemia, 4. Has undergone HSCT and have not had adequate hematologic recovery (Recovery is defined as peripheral absolute neutrophil count (ANC) = 1 × 10^9/L and platelets at least = 50 × 10^9/L [but preferably = 100 × 10^9/L] and signs of a cellular BM), 5. Patients on immunosuppressive therapy post HSCT must be off all immunosuppression therapy within 2 weeks of Cycle 1 Day 1, 6. = Grade 2 active GvHD, moderate or severe limited chronic GvHD, or extensive chronic GvHD of any severity, 7. Has received prior menin inhibitor, 8. Has received chemotherapy, immunotherapy, radiotherapy (unless if given for management of CNS leukemia), or any ancillary therapy that is considered to be investigational (ie, used for non-approved indications(s) and in the context of a research investigation) < 14 days prior to the first dose of ziftomenib or within 5 drug half-lives prior to the first dose of study drug, whichever is shorter, to ensure that patient time without necessary AML therapy is appropriately limited, 9. Requires treatment with concomitant drugs that are strong inhibitors or inducers of CYP3A4 with the exception of antibiotics, antifungals, and antivirals that are used as SOC to prevent or treat infections. Other such drugs that are considered absolutely essential by the Investigator for the care of the patient should be discussed on a case-by-case basis with the Kura Medical Monitor
研究者
相似试验
进行中（未招募）
1 期
First in human clinical trial of the study drug KO-539 in patients with leukemiaRelapsed and/or refractory Acute Myeloid LeukemiaMedDRA version: 21.0Level: LLTClassification code 10060558Term: Acute myeloid leukemia recurrentSystem Organ Class: 100000004864EUCTR2019-001545-41-ITKURA ONCOLOGY INC90
进行中（未招募）
1 期
First in human clinical trial of the study drug KO-539 in patients with leukemiaRelapsed and/or refractory Acute Myeloid LeukemiaMedDRA version: 21.0Level: LLTClassification code 10060558Term: Acute myeloid leukemia recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-001545-41-DEKura Oncology, Inc.236
未知
1 期
Phase I, Multiple Dose Study of MLN0002 in Patients with Ulcerative Colitislcerative ColitisJPRN-jRCT2080221099Takeda Pharmaceutical Company Limited12
进行中（未招募）
1 期
A first-in-human study to evaluate the clinical activity of JNJ-63723283 in patients with advanced cancers.EUCTR2016-002017-22-ESJanssen-Cilag International NV169
进行中（未招募）
1 期
A First-in-Human, Open-label, Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced CancersAdvanced Stage Solid TumorsMedDRA version: 21.0Level: LLTClassification code: 10049280Term: Solid tumour Class: 10029104CTIS2023-506144-16-00Janssen - Cilag International6